Göttingen, Germany | March 26, 2026

The life science group Sartorius held its Annual General Meeting today. The shareholders approved all proposals of the Supervisory Board and the Executive Board by a large majority, including the dividend proposal of 0.74 euros per preference share and 0.73 euros per ordinary share. The total amount disbursed will be 50.8 million euros, with the dividend to be paid out to shareholders on March 31, 2026.

Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. With around 60 production and sales locations worldwide, the Göttingen-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3.5 billion euros. More than 14,000 employees serve customers around the globe.